<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240980</url>
  </required_header>
  <id_info>
    <org_study_id>MB125-001</org_study_id>
    <nct_id>NCT01240980</nct_id>
  </id_info>
  <brief_title>Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) &amp; Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 &amp; 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-903452 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and effect on blood glucose
      control of BMS-903452 compared to placebo in healthy subjects &amp; relative bioavailability of
      the crystalline and amorphous forms of BMS-903452 [Panels 4,6,11 &amp; 12(Part A)] ; and subjects
      with type 2 Diabetes Mellitus (Part B). The study will also determine the amount of
      BMS-903452 in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of the investigational drug, as assessed by adverse event monitoring, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments</measure>
    <time_frame>Within 10 days of study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity of the investigational drug on glucose and hormones regulating glucose metabolism</measure>
    <time_frame>Within 2 days of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on electrocardiographic (ECG) parameters</measure>
    <time_frame>Within 10 days of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent urinary recovery (% UR)</measure>
    <time_frame>Within 10 days of study drug administration</time_frame>
    <description>derived by non-compartmental methods by a validated pharmacokinetic program. Actual times will be used for the analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR) from plasma</measure>
    <time_frame>Within 10 days of study drug administration</time_frame>
    <description>derived by non-compartmental methods by a validated pharmacokinetic program. Actual times will be used for the analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single-dose pharmacokinetics parameter maximum observed concentration in plasma (Cmax) of BMS-903452 will be derived from the plasma concentration versus time data</measure>
    <time_frame>Within 10 days after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single-dose pharmacokinetics parameter time to reach maximum observed concentration in plasma (Tmax) of BMS-903452 will be derived from the plasma concentration versus time data</measure>
    <time_frame>Within 10 days after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single-dose pharmacokinetics parameter time Area under the plasma concentration-time curve from time zero extrapolated to infinity AUC(INF) of BMS-903452 will be derived from the plasma concentration versus time data</measure>
    <time_frame>Within 10 days after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single-dose pharmacokinetics parameter Area under the plasma concentration-time curve from time zero to last measurable sampling time AUC (0-T) of BMS-903452 will be derived from the plasma concentration versus time data</measure>
    <time_frame>Within 10 days after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single-dose pharmacokinetics parameter Terminal-phase elimination half-life in plasma (T-Half) of BMS-903452 will be derived from the plasma concentration versus time data</measure>
    <time_frame>Within 10 days after study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single-dose pharmacokinetics parameter apparent clearance from plasma after extra-vascular administration (CLT/F) of BMS-903452 will be derived from the plasma concentration versus time data</measure>
    <time_frame>Within 10 days after study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>BMS-903452 (0.1 mg) or Placebo - A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Healthy Subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-903452 (0.6 mg) or Placebo - A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Healthy Subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-903452 (3.0 mg) or Placebo - A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Healthy Subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-903452 (10 mg) or Placebo - A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Healthy Subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-903452 (30 mg) or Placebo - A5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Healthy Subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-903452 (60 mg) or Placebo - A6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Healthy Subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-903452 (120 mg) or Placebo - A7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Healthy Subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-903452 (0.6 mg) or Placebo - B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Subjects with type 2 Diabetes Mellitus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-903452 (10 mg) or Placebo - B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Subjects with type 2 Diabetes Mellitus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-903452 (120 mg) or Placebo - B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Subjects with type 2 Diabetes Mellitus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-903452 (10 mg) or Placebo - A11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Healthy Subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-903452 (60 mg) or Placebo - A12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Healthy Subjects)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Solution, Oral, 0.1 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (0.1 mg) or Placebo - A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Solution, Oral, 0.6 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (0.6 mg) or Placebo - A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Suspension, Oral, 3.0 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (3.0 mg) or Placebo - A3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Suspension, Oral, 10 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (10 mg) or Placebo - A4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Suspension, Oral, 30 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (30 mg) or Placebo - A5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Suspension, Oral, 60 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (60 mg) or Placebo - A6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Suspension, Oral, 120 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (120 mg) or Placebo - A7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution, Oral, 0 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (0.1 mg) or Placebo - A1</arm_group_label>
    <arm_group_label>BMS-903452 (0.6 mg) or Placebo - A2</arm_group_label>
    <arm_group_label>BMS-903452 (0.6 mg) or Placebo - B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Suspension, Oral, 0 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (3.0 mg) or Placebo - A3</arm_group_label>
    <arm_group_label>BMS-903452 (10 mg) or Placebo - A4</arm_group_label>
    <arm_group_label>BMS-903452 (30 mg) or Placebo - A5</arm_group_label>
    <arm_group_label>BMS-903452 (60 mg) or Placebo - A6</arm_group_label>
    <arm_group_label>BMS-903452 (120 mg) or Placebo - A7</arm_group_label>
    <arm_group_label>BMS-903452 (10 mg) or Placebo - B2</arm_group_label>
    <arm_group_label>BMS-903452 (120 mg) or Placebo - B3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Suspension using crystalline form, Oral, 10 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (10 mg) or Placebo - A11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Suspension using crystalline form, Oral, 60 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (60 mg) or Placebo - A12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Suspension using crystalline form, Oral, 0 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (10 mg) or Placebo - A11</arm_group_label>
    <arm_group_label>BMS-903452 (60 mg) or Placebo - A12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Solution, Oral, 0.6 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (0.6 mg) or Placebo - B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Suspension, Oral, 10 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (10 mg) or Placebo - B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-903452</intervention_name>
    <description>Suspension, Oral, 120 mg, once daily, 1 day</description>
    <arm_group_label>BMS-903452 (120 mg) or Placebo - B3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically healthy or Clinical diagnosis of Type 2 diabetes on a stable dose of
             metformin monotherapy

        Exclusion Criteria:

          -  Type 1 Diabetes

          -  History of significant heart disease

          -  Prior bariatric surgery

          -  Women of childbearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Phase One</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ppd Development, Lp</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

